Opens in a new tab

Breaking news

Kailera’s Bold Bet: Skipping The Lab, Racing To Market With China’s Ozempic Rivals

While Big Pharma pours billions into obesity drug R&D, a new biotech startup is taking a shortcut: licensing ready-to-go therapies from China. Kailera Therapeutics, launched with $400 million from Bain Capital, Atlas Venture, and RTW Investments, is fast-tracking four obesity drugs developed by Jiangsu Hengrui — one of China’s pharmaceutical heavyweights.

The playbook? Bypass years of early-stage research. “We saw next-gen GLP-1 therapies that could leapfrog existing options,” says Dr. Amir Zamani, Bain’s life sciences partner who spearheaded the deal. One injectable candidate from Hengrui showed 59% of patients losing 20 %+ body weight in Phase II trials, with mild side effects. Even more promising: two of the licensed drugs are pills, a potential game-changer in a market currently dominated by injectables.

With global obesity drug sales projected to hit $131 billion by 2028, Kailera aims to move fast. Leading the charge is biotech veteran Ron Renaud, who’s sold three companies for a combined $16 billion. “We likely have the most advanced and diverse weight-loss pipeline outside Big Pharma,” he says. The goal is to bring the first drug to market by 2030 — a rapid timeline thanks to Hengrui’s head start.

China’s rise as a pharmaceutical R&D hub is reshaping the biotech map. Over a third of molecules licensed by Western firms now originate there. U.S. firms have spent $8.1 billion since 2020 licensing Chinese-developed drugs — a stark contrast to just $536 million in the previous five years.

Kailera is betting this east-west fusion can deliver blockbuster results. With 100 million obese adults in the U.S. alone — not to mention global demand — the addressable market is massive. “This isn’t a one-drug race,” Renaud says. “It’s going to take an entire arsenal.”

To prep for launch, Kailera has added top-tier talent: Scott Wasserman, former cardiovascular lead at Amgen, is chief medical officer; Jamie Coleman, who led Zepbound’s commercial rollout at Lilly, now heads marketing.

Whether Kailera becomes the next independent giant or is eventually snapped up by Big Pharma, as Renaud’s previous ventures were, it’s already a standout in the white-hot weight-loss drug race.

Cyprus Plans €20 Million In Grants For Business Solar Energy Storage

Cyprus plans to allocate €20 million in grants in 2027 and 2028 to help businesses store electricity generated by solar panels, aiming to reduce energy costs and increase the use of renewable power.

Energy Minister Michael Damianos announced the proposed scheme at the annual general meeting of the Famagusta Chamber of Commerce and Industry in Deryneia. The programme would support both businesses already generating solar electricity for their own consumption and those planning to install solar panels.

New Grants To Support Solar Storage And Young Entrepreneurs

Combining solar panels with energy storage systems would allow businesses to use more of the electricity they generate instead of relying on the grid when solar production is unavailable. This could help companies with high energy consumption manage their operating costs.

The ministry is also preparing a separate, simplified grant scheme for entrepreneurs aged 18 to 35. The programme is expected to open in the first quarter of 2027.

Ministry Secures €352 Million For Business Support

Damianos said the ministry had secured €352 million for grant programmes under the 2021–2027 programming period. The funding covers initiatives supporting energy and digital upgrades, manufacturing and the circular economy.

Between the beginning of 2021 and the end of September 2026, the ministry paid more than €151 million against nearly 5,500 grant payment requests, he added.

Frenaros Industrial Estate Approaches Full Occupancy

The Frenaros industrial estate is now home to 47 businesses, while all 64 available plots have either been offered to companies or leased, according to the minister.

Funding has also been approved for new signs at the estate’s entrances, while a study on fencing is nearing completion. The ministry will cover the costs of the planned improvements.

Exports And Investment Strategy

Cyprus exported €1.37 billion worth of domestically produced goods in 2025, marking a 10% increase from 2024, excluding mineral fuels and petroleum products. Services exports also grew, rising 6% to €32 billion, Damianos said.

He added that consultations on Cyprus’ strategy for attracting businesses and talent for 2027–2030 had concluded. The plan aims to attract investment and skilled professionals while strengthening links between incoming companies and the local economy.

The Future Forbes Realty Global Properties
eCredo
Uol
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter